Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.38 |
| ▸ | CDK2 | P24941 | 1/20 | 0.38 |
| ▸ | FEN1 | P39748 | 2/20 | 0.35 |
| ▸ | KDR | P35968 | 5/20 | 0.34 |
| ▸ | FLT1 | P17948 | 2/20 | 0.34 |
| ▸ | FLT4 | P35916 | 2/20 | 0.34 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.32 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14290309 | 0.87 | NPC1 (0.47) | NPC1RAB9ASMN1; SMN2KDM4EMEN1 | |
| SCHEMBL4717668 | 0.82 | KDM4E (0.36) | NPC1RAB9ASMN1; SMN2KDM4EMEN1 | |
| SCHEMBL4716769 | 0.78 | FEN1 (0.36) | FEN1GRM2 | |
| SCHEMBL4717663 | 0.77 | GGPS1 (0.37) | KDM4EALDH1A1FEN1GRM2 | |
| SCHEMBL4717169 | 0.73 | ABCC8 (0.36) | KDM4EALDH1A1FEN1GRM2 | |
| SCHEMBL4718724 | 0.71 | ATP4A (0.46) | MEN1KMT2AGRM2 | |
| SCHEMBL4716835 | 0.70 | GGPS1 (0.58) | NPC1RAB9A | |
| SCHEMBL4714556 | 0.70 | HTT (0.36) | KDM4EALDH1A1KMT2A | |
| SCHEMBL14408925 | 0.68 | GRM2 (0.48) | FEN1KDRGRM2 | |
| SCHEMBL14408924 | 0.67 | KDM4E (0.40) | NPC1RAB9ASMN1; SMN2KDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1448561-B1 | BETA 3 ADRENERGIC AGONISTS | LILLY CO ELI (US) | 2008-02-20 | — | — | EP | disclosed |
| US-7265127-B2 | β3 adrenergic agonists | ELI LILLY AND COMPANY (US) | 2007-09-04 | — | — | US | disclosed |
| US-7253181-B2 | β3 adrenergic agonists | ELI LILLY AND COMPANY (US) | 2007-08-07 | — | — | US | disclosed |
| US-7241772-B2 | β3 adrenergic agonists | ELI LILLY AND COMPANY (US) | 2007-07-10 | — | — | US | disclosed |
| US-7205407-B2 | 3-Substituted oxindole β3 agonists | ELI LILLY AND COMPANY (US) | 2007-04-17 | — | — | US | disclosed |
| US-7071208-B2 | β3 Adrenergic agonists | ELI LILLY AND COMPANY (US) | 2006-07-04 | — | — | US | disclosed |
| US-20060142328-A1 | BETA 3 ADRENERGIC AGONISTS | JPMORGAN CHASE BANK, N.A., AS SUCCESSOR COLLATERAL AGENT | 2006-06-29 | — | — | US | disclosed |
| US-20060142327-A1 | BETA 3 ADRENERGIC AGONISTS | JPMORGAN CHASE BANK, N.A., AS SUCCESSOR COLLATERAL AGENT | 2006-06-29 | — | — | US | disclosed |
| US-20060142329-A1 | BETA 3 ADRENERGIC AGONISTS | JPMORGAN CHASE BANK, N.A., AS SUCCESSOR COLLATERAL AGENT | 2006-06-29 | — | — | US | disclosed |
| EP-1448560-B1 | 3-SUBSTITUTED OXINDOLE beta 3 AGONISTS | LILLY CO ELI (US) | 2005-06-15 | — | — | EP | disclosed |
| US-20050020618-A1 | Beta 3 adrenergic agonists | JPMORGAN CHASE BANK, N.A., AS SUCCESSOR COLLATERAL AGENT | 2005-01-27 | — | — | US | disclosed |
| US-20050020617-A1 | 3-substituted oxindole beta3 agonists | JPMORGAN CHASE BANK, N.A., AS SUCCESSOR COLLATERAL AGENT | 2005-01-27 | — | — | US | disclosed |
| EP-1448561-A1 | BETA 3 ADRENERGIC AGONISTS | ELI LILLY AND COMPANY (US) | 2004-08-25 | — | — | EP | disclosed |
| EP-1448560-A1 | 3-SUBSTITUTED OXINDOLE $g(b)3 AGONISTS | ELI LILLY AND COMPANY (US) | 2004-08-25 | — | — | EP | disclosed |
| WO-2003044017-A1 | BETA 3 ADRENERGIC AGONISTS | ELI LILLY AND COMPANY (US) | 2003-05-30 | — | — | WO | disclosed |
| WO-2003044016-A1 | 3-SUBSTITUTED OXINDOLE β3 AGONISTS | ELI LILLY AND COMPANY (US) | 2003-05-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060142329-A1 | BETA 3 ADRENERGIC AGONISTS | ADRB3, ADRB1, ADRB2 | NPC1 1332/4885RAB9A 1227/4885SMN1; SMN2 2965/4885 |
| US-20050020618-A1 | Beta 3 adrenergic agonists | ADRB3, ADRB1, ADRB2 | NPC1 1332/4885RAB9A 1227/4885SMN1; SMN2 2965/4885 |
| US-20050020617-A1 | 3-substituted oxindole beta3 agonists | ADRB3, ADRB2, ADRA2C | NPC1 2981/4885RAB9A 2454/4885SMN1; SMN2 3697/4885 |
| US-20060142328-A1 | BETA 3 ADRENERGIC AGONISTS | ADRB3, ADRB1, ADRB2 | NPC1 1332/4885RAB9A 1227/4885SMN1; SMN2 2965/4885 |
| US-20060142327-A1 | BETA 3 ADRENERGIC AGONISTS | ADRB3, ADRB1, ADRB2 | NPC1 1045/4885RAB9A 1407/4885SMN1; SMN2 2394/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.